AbbVie Inc. (ABBV)
NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-market:
| Previous close | 159.62 |
| Open | 159.59 |
| Bid | 161.05 x 800 |
| Ask | 161.55 x 1000 |
| Day's range | 158.56 - 161.55 |
| 52-week range | 130.96 - 182.89 |
| Volume | |
| Avg. volume | 5,765,625 |
| Market cap | 285.995B |
| Beta (5Y monthly) | 0.56 |
| PE ratio (TTM) | 48.07 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 6.20 (3.84%) |
| Ex-dividend date | 12 Apr 2024 |
| 1y target est | N/A |
- Insider Monkey
AbbVie Inc. (NYSE:ABBV) Q1 2024 Earnings Call Transcript
AbbVie Inc. (NYSE:ABBV) Q1 2024 Earnings Call Transcript April 26, 2024 AbbVie Inc. beats earnings expectations. Reported EPS is $2.31, expectations were $2.26. AbbVie Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning and thank you for standing […]
- Simply Wall St.
Earnings Beat: AbbVie Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
AbbVie Inc. ( NYSE:ABBV ) investors will be delighted, with the company turning in some strong numbers with its latest...
- Investor's Business Daily
AbbVie Outlook: Why Humira Biosimilars Won't Undo Huge Sales
Fears that Humira biosimilars will erode AbbVie's topline are overblown, an analyst said Monday. He has an outperform rating on AbbVie stock.
© 2024 Yahoo. All rights reserved.